MoUJul 30, 2026, 06:03 AM
EUDA Health Details Cell Therapy Program with GO POSB & SIIT
AI Summary
EUDA Health Holdings Ltd provided additional details on its integrated cell therapy program under a non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. EUDA Health will fund the collaboration and facilitate commercialization, while GO POSB will contribute its iPSC platform and tumor organoid bank, and SIIT will provide NK/NK-TCR cell engineering and GMP manufacturing. The partnership aims to develop next-generation off-the-shelf cell therapies for wellness and oncology, with the CEO highlighting the potential for a 'game changer' in the market.
Key Highlights
- EUDA Health to fund, commercialize, and support global market access for the cell therapy program.
- GO POSB to provide its proprietary iPSC platform and clinical-grade universal tumor organoid bank.
- SIIT to offer NK and NK-TCR cell engineering capabilities and GMP manufacturing expertise.
- The collaboration aims to develop off-the-shelf cell therapies for wellness and oncology applications.
- The Memorandum of Understanding (MOU) was signed on July 15, 2026.
Price Impact
More from EUDA